Surgical Critical Care Initiative

About SC2i

The Surgical Critical Care Initiative (SC2i) advances the care of critically ill combat casualties and civilian patients by leveraging precision medicine that integrates biomarkers, clinical data, and artificial intelligence.

SC2i was established in 2013 to develop biomarker-driven Clinical Decision Support Tools (CDSTs) to guide clinicians in the treatment of critically ill patients. SC2i is a consortium of seven federal and non-federal entities focusing on the development, translation, and clinical validation of data-driven approaches toward surgical critical care. It capitalizes on unprecedented advances in combat casualty care and surgical research now emanating from military experience with critically injured service men and women. In addition, SC2i partners with the DoD as well as civilian academic surgeons to allow for the evolution and refinement of the best practices for the care of critically injured patients.

SC2i focuses on paradigm-shifting approaches to patient management that combine biological data assimilation with protocolized decision support algorithms to provide the best treatment decisions for clinicians. The partnering of the DoD with civilian trauma centers will speed the validation and implementation of evolving surgical practices within the military, while leveraging insights gained from military experiences to improve civilian surgical quality. 

SC2i has enrolled more than 2,400 patients with biospecimens as well as an additional 2,900 patients enrolled with data only. It has aggregated more than 68 million data elements in its central data repository to power the development of more than a dozen CDSTs. SC2i implemented a strategic pivot in 2020 by launching product teams to expedite the development of two of its most advanced CDSTs: Artificial Intelligence Sepsis Expert (AISE) and WounDx™.